hotspot -WSS

hotspot

author：comprehensive 2025-09-06 07:38:57 - browse：25

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： David Liu startup to focus on CRISPR delivery

Wikipedia

WSS

Eli Lilly CEO gives to Mike Pence presidential super PAC

Mystery swirls around US soldier who entered North Korea days ago, officials say

'A game

People with substance use disorder deserve online privacy

Why the drug industry's warnings on the IRA's impact fall short

House panel takes first step toward fixing drug shortages

leisure time

hotspot

entertainment

Hollywood unions extend contract negotiations for actors

Grad students accuse University of California of wage theft

Wildfire smoke exposes gaps in outdoor worker protections

Eli Lilly CEO gives to Mike Pence presidential super PAC

In Memoriam: Notable people who died in 2023

'CMA Fest' 2023: How to watch, who is performing and more

The cancer drug shortage isn’t new — and neither are the solutions

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Novavax promises a turnaround & Lilly roils the obesity market

How the messy conversation about Dolly changed bioethics

focus

Information blocking fines are now fair game in health care

After a decade, new Gardasil ad campaign gets it (mostly) right

The struggle to figure out which patients 'deserve' Wegovy

Why the drug industry's warnings on the IRA's impact fall short

Mystery swirls around US soldier who entered North Korea days ago, officials say

Eli Lilly CEO gives to Mike Pence presidential super PAC

Wikipedia

focus

entertainment

leisure time